TCGA-CN-A6V7-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.640
- E2F_TARGETS+0.560
- MYC_TARGETS_V2+0.420
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V1+0.400
- DNA_REPAIR+0.340
- FATTY_ACID_METABOLISM+0.310
- PEROXISOME+0.260
- ADIPOGENESIS+0.230
- SPERMATOGENESIS+0.230
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.640
- ANGIOGENESIS-0.580
- IL6_JAK_STAT3_SIGNALING-0.470
- TGF_BETA_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.420
- UV_RESPONSE_DN-0.420
- HEDGEHOG_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.400
- MYOGENESIS-0.400
- COAGULATION-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.944 |
| 2 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.921 |
| 3 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.914 |
| 4 | TCGA-BH-A0HU-01A-11R-A034-07 | — | B | 0.911 |
| 5 | SRR26320088 | — | — | 0.909 |
| 6 | SRR6013549 | — | cohortSQ2 | 0.909 |
| 7 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.908 |
| 8 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.905 |
| 9 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.903 |
| 10 | C3L-00993 | — | cohortSQ1 | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.640 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |